Status:
WITHDRAWN
The vBlocT2D Study
Lead Sponsor:
Kaiser Permanente
Conditions:
Type2 Diabetes
Obesity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Overall aim: To demonstrate that weight loss through vBloc Therapy in combination with usual care will achieve better glycemic control for patients with obesity and type 2 diabetes than usual care alo...
Detailed Description
The vBlocT2D study is a two arm, randomized, controlled, unblinded clinical trial in which 60 adult patients with T2D with moderate to extreme obesity (BMI 35-45 kg/m2) and suboptimal glycemic control...
Eligibility Criteria
Inclusion
- Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND
- Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND
- Age 18 years or older, AND
- Body mass index (BMI) 35-45 kg/m2 inclusive, AND
- Attempt and failed diet, exercise and behavioral modification program within past five years,
Exclusion
- Use of GLP-1 receptor agonists for diabetes currently or within past 6 months
- Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators))
- Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body)
- Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation
- Previous bariatric or upper GI surgery
- Excessive alcohol intake
- Current smokers or smoking cessation in prior 3 months
- An underlying disease known to have important effects on glucose metabolism
- Active infections
- Anemia (Hemoglobin \<11g/dl in women, \<12 g/dl in men) or known coagulopathy
- Chronic kidney disease manifest as serum creatinine \>2.0 mg/dl
- Diabetic retinopathy requiring photocoagulation therapy
- Symptomatic diabetic gastroparesis
- Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure
- Cirrhosis of the liver, portal hypertension, or esophageal varices
- Symptomatic esophageal reflux
- Conditions or behaviors likely to affect the conduct of the vBloc Study
- Unable or unwilling to give informed consent
- Unable to adequately communicate with clinic staff
- Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study
- Likely to move away from participating clinic in next 2 years
- Current (or anticipated) pregnancy and lactation.
- Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study
- Weight loss \>7% in past two months for any reason except postpartum weight loss.
- Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.
Key Trial Info
Start Date :
February 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03355092
Start Date
February 23 2018
End Date
November 30 2018
Last Update
April 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente South Bay Medical Center
Harbor City, California, United States, 90710